ArticleFrontiers in microbiology2020
Antimycobacterial Potential of Mycobacteriophage Under Disease-Mimicking Conditions.
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Review
- Activity of a three-phage combination againstbioRxiv : the preprint server for biology · 2026Article
- Genomic profile and infection dynamics of Kashi_RDG1 (KRDG1), a novel cluster K1 mycobacteriophage infecting mycobacterial hosts.Frontiers in microbiology · 2026Article
- Mycobacteriophage Yasnaya_Polyana and its engineered lytic derivative: specificity of regulatory motifs and lytic potential.Frontiers in microbiology · 2025Article
- Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae.Scientific reports · 2024Article
- Mycobacteriophages and Their Applications.Antibiotics (Basel, Switzerland) · 2024Review
- Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis.BMC microbiology · 2024Article
- Picolinic acid is a broad-spectrum inhibitor of enveloped virus entry that restricts SARS-CoV-2 and influenza A virus in vivo.Cell reports. Medicine · 2023Article
- Ecology and Evolutionary Biology of Hindering Phage Therapy: The Phage Tolerance vs. Phage Resistance of Bacterial Biofilms.Antibiotics (Basel, Switzerland) · 2023Review
- Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections.Frontiers in microbiology · 2023Review
- Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.BMC infectious diseases · 2022Review
- Article
- A Review on Mycobacteriophages: From Classification to Applications.Pathogens (Basel, Switzerland) · 2022Review
- Article
- P22 Phage Shows Promising Antibacterial Activity under Pathophysiological Conditions.Archives of microbiology & immunology · 2022Article
- Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment.Microorganisms · 2021Review
- Article
- Antimycobacterial Potential of Mycobacteriophage Under Disease-Mimicking Conditions.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance continues to be a major global health risk with an increase in multi-drug resistant infections seen across nearly all bacterial diseases. Mycobacterial infections such as Tuberculosis (TB) and Non-Tuberculosis infections have seen a significant increase in the incidence of multi-drug resistant and extensively drug-resistant infections. With this increase in drug-resistant Mycobacteria, mycobacteriophage therapy offers a promising alternative. However, a comprehensive study on the infection dynamics of mycobacteriophage against their host bacteria and the evolution of bacteriophage (phage) resistance in the bacteria remains elusive. We aim to study the infection dynamics of a phage cocktail against Mycobacteria under various pathophysiological conditions such as low pH, low growth rate and hypoxia. We show that mycobacteriophages are effective against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.